Pfizer and Valneva said they will seek regulatory approval for a Lyme disease vaccine after a successful late-stage trial. Approval would add a new vaccine to Pfizer's and Valneva's portfolios and could move the companies' shares by low single-digit percentages pending review, commercial details and any additional efficacy/safety data.
Pfizer and Valneva said they will seek regulatory approval for a Lyme disease vaccine after a successful late-stage trial. Approval would add a new vaccine to Pfizer's and Valneva's portfolios and could move the companies' shares by low single-digit percentages pending review, commercial details and any additional efficacy/safety data.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
